MilliporeSigma invests €300M in new bioprocessing site in Daejeon, South Korea
MilliporeSigma, the Life Science business of Merck KGaA, is investing more than €300 million to build a new Bioprocessing Production Center in Daejeon, South Korea, expected to create up to 300 jobs by 2028.
Value
$326.0M (300.0M EUR)
Capacity
43,000 square meters
Productsdry powder cell culture mediaprocess liquidssterile sampling systemsbiotech products for biologics
“The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date.”wolfmediausa.com
- 2 sources
- wolfmediausa.comNews Release: MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Koreaeporter onMar 20, 2024
- businesswire.comMilliporeSigma Invests More than € 300 Million in New Life Science Production Site in KoreaRachel Bloom BaglinMar 20, 2024
Summarized from public sources; check the original articles before acting on it.
ENDATA